Notice ID: c418c9f44b534339939d87e2d6098a32Solicitation
NIAID CLINICAL PRODUCTS CENTER (CPC)
Archived on February 1, 2025. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 3:00 PM UTC−05:00
- Posted
- October 18, 2024
- Notice type
- Solicitation
- Set-aside
- Total Small Business Set-Aside (FAR 19.5)
- NAICS
- 541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH NIAID
- Last updated
- Jan 23, 2026
Identifiers
- Solicitation number
- RFP-NIAID-75N93024R00018
- Notice ID
- c418c9f44b534339939d87e2d6098a32
Description
The purpose of this contract is to provide support to NIAID OPRM for the pharmacy and pharmaceutical oversight responsibilities of national and international NIAID/DAIT supported clinical trials as well as other NIH funded clinical trials on an as-needed basis, to ensure study product integrity, participant safety, pharmacy and pharmaceutical regulatory compliance. This contract provides NIAID with centralized services for: 1) Study Product (i.e., IP management, procurement, receipt, storage, labeling, packaging/repackaging, blinding (i.e., over-encapsulation); placebo manufacturing, sterile product manufacturing and preparation, blister packaging, distribution to site, inventory management, accountability, disposal, and expiration dates and recall monitoring); 2) IP Regulatory Document Maintenance in the DRMC (Regulatory documents relating to shipment, receipt, disposition, return, destruction, manufacturing (placebo, food product immunotherapy, etc.), over-encapsulation (for blinding purposes), stability/sterility protocols and testing, and labeling and packaging; 3) Co-submissions of Drug Master Files (DMFs) and co-conducting product stability studies; and 4) Clinical samples repository, product sterility/stability and release testing, clinical laboratory testing such as Immunoassays, Molecular Diagnostics, DNA Sequencing, Flow Cytometry, etc.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
Showing 1 of 1 items
Document | Source | Agency | Posted Date | File Size | Actions | |
|---|---|---|---|---|---|---|
| Solicitation | NATIONAL INSTITUTES OF HEALTH | Oct 18, 2024 | - |
Lifecycle
Solicitation:
RFP-NIAID-75N93024R00018- Solicitation
Award typically follows within 30–90 days after the response deadline. (estimate)
- SolicitationCurrentOct 18, 2024
NIAID CLINICAL PRODUCTS CENTER (CPC)
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
This is a Small Business Sources Sought (SBSS) Notice for Research and Development (R&D). This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of qualified small businesses under the size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and the small business size standard for such requirements is 1,000 employees or less, including applicable affiliates. This SBSS notice is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. The purpose of this synopsis is to identify small business organizations with requisite qualifications to provide the services stated herein. Based on capability statements received in response to this Sources Sought Announcement, this acquisition may be solicited as a small business set-aside. All small business organizations (SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB) are encouraged to respond to this notice. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. | 85% | Market Research | 11/23/2026 |
This is a Request for Information (RFI) for Research and Development (R&D) open to all interested organizations, regardless of business size. This is NOT a solicitation for capability statements, proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain industry input to inform requirements development and acquisition planning for the proposed research services described in the attached draft Statement of Work (SOW). The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). This RFI is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. Interested organizations are encouraged to review the attached draft SOW and respond to the information requests outlined in this notice. The Government anticipates issuing a solicitation for this requirement at a later date under a separate announcement. Issuance of this notice does not obligate the Government to issue a solicitation or award a contract. | 84% | Special Notice | 11/17/2026 |
Anticipated Period of Performance The anticipated period of performance is February 1, 2027 through January 31, 2028, with an option to extend services for an additional 6 month period, through July 31, 2028. Anticipated award date: February 1, 2027 The NAICS Code is 541715. Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Allergy, Immunology, and Transplantation (DAIT) has a requirement to support a broad range of services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. The major clinical research programs to be supported by this solicitation include, Autoimmunity Centers of Excellence and Immune Tolerance Network (ACE), as well as investigator initiated clinical trials (IICT), and other clinical trials or study activities supported by NIAID herein collectively referred to as NIAID supported research. Description Topic Title: Autoimmune Diseases Statistical & Clinical Coordinating Center (ADSCCC) The Division of Allergy, Immunology, and Transplantation (DAIT), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), project is for work related to the contract below: “Autoimmune Diseases Statistical & Clinical Coordinating Center (AD-SCCC)”, RHO Federal Systems Division, Inc. (Contract 75N93022C00003) This contract was awarded on a competitive basis for a five-year period from February 1, 2022 through January 31, 2027. A term type/level of effort contract was awarded for the delivery of 56,170 direct labor hours per year for Years 1-5. The total value of the contract is $49,268,667 and includes options for extension of the term for a total performance period of 5 years and options for increases in the level of effort, with the purpose of establishing an Autoimmune Diseases Statistical & Clinical Coordinating Center (AD- SCCC) that will provide a broad range of support critical for the design, development, execution, and analysis of clinical research sponsored by NIAID in autoimmune diseases and diseases related to mucosal immunology and primary immune deficiencies. The scope of clinical research to be supported by the AD- SCCC includes: (i) clinical trials at all phases to evaluate the safety and efficacy of investigational products and innovative approaches for disease treatment and prevention; (ii) studies of underlying mechanisms as integral components of clinical trials; (iii) clinical studies (e.g., genetic studies, microbiome studies, surveys of current therapies, etc.); and (iv) surrogate/biomarker studies. The scope of statistical and clinical support functions to be performed by the AD-SCCC includes statistical design and analysis; protocol development; study initiation and management; clinical safety and pharmacovigilance support; safety oversight; management of clinical study collaboration portals; manuscript preparation and management of sample repositories. The NIAID, NIH, conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. The causes, pathogenesis, diagnosis, treatment, and prevention of autoimmune diseases are major areas of emphasis for NIAID’s Division of Allergy, Immunology, and Transplantation (DAIT). DAIT pursues research on autoimmune diseases by supporting investigator-initiated research projects, cooperative clinical studies, national networks of research centers, and demonstration and education research projects. A critical component of the Division’s mission focuses on clinical research to develop new and/or improved strategies to treat or prevent autoimmune diseases through rigorous evaluations of the safety and efficacy of investigational products and therapeutic interventions, studies to elucidate underlying mechanisms of disease, studies to develop and evaluate surrogate/biomarkers of disease stage, severity and progression, and clinical studies of disease natural history. The purpose of this acquisition is to extend the period of performance of the current contract (through July 31, 2028), beginning February 1, 2027, thereby maintaining the same direct labor hours to maintain ongoing clinical trial operations while DAIT completes the competition under the Clinical Data, Safety, and Coordinating Centers (CDSCC) NOFO. The extension retains the existing scope and contract type. The required research and development clinical trial activities are severable in nature, the 18-month extension will be structured as two discrete option periods. Specifically, the Contractor will be responsible for the following: A. Statistical Design Provide expertise, advice and assistance pin the development of statistical design plans for the development of concept and full study proposals for NIAID supported clinical research; Provide assistance in the preparation of concept and full proposals and study-specific protocols; Provide assistance in the preparation of concept and full proposals and protocols for mechanistic studies; Provide support for preclinical safety study evaluation by providing statistical expertise for, and participate in, evaluating the accuracy and validity of data from preclinical safety studies in support of clinical trials if applicable; Provide assistance for clinical trials and mechanistic studies post-study initiation. B. Statistical Analysis Development and preparation of the Statistical Analysis Plan (SAP) for each clinical trial in conjunction with the Study Management Teams (SMTs); Preparation of interim and final analyses; Preparation of summary data reports; Development and preparation of results for posting as required by ClinicalTrials.gov; Review of the accuracy and completeness of statistical data and data analyses for all abstracts, manuscripts, and presentations reporting on the clinical studies conducted by the relevant NIAID-sponsored networks and investigators prior to presentation or submission for publication. Collaboration with NIAID-supported research, including the NIAID Clinical Data and Safety Management Center (CDSMC); C. Protocol Development and Study Initiation Provide expert advice and assistance to SMTs in the development of protocols for clinical trials and mechanistic studies; Provide expert advice, assistance and coordination in the preparation, writing, review and approval of protocol-related documents and materials in collaboration with NIAID, SMTs, and the CDSMC and other NIAID supported research. D. Data Management and Reporting E. Clinical Safety and Pharmacovigilance Center Support F. Safety Oversight Structure Support G. Clinical Study Internet-Based Collaboration Portals H. Training I. Repository of Biological Specimens J. Other Technical and Administrative Support K. Scientific and Technical Personnel L. Facilities, Equipment and Other Resources M. Quality Assurance/Quality Control N. Overall Project Management O. Initial and Final Transitions The NIAID intends to negotiate, under the authority of RFO - FAR Part 6.302-1 and HHSAR Part 306.302-1, on a sole source basis with Rho, to modify the existing contract to extend the current contract by a total of 18-months [Term Option 5 (12-months, February 1, 2027 through January 31, 2028), and Term Option 6 (6-months, February 1, 2028 through July 31, 2028)]. Due to the complex nature of DAIT clinical trial operations and the need for a contractor to perform the required AD-SCCC services during the interim period, the requirement is to maintain support for the existing portfolio without an interruption in protocol operations, statistical support, data coordination, or safety oversight beginning February 1, 2027. Rho’s demonstrated personnel qualifications, staffing, relevant experience, and current protocol-specific knowledge support its ability to meet that requirement. Attempting to bring in a new contractor would result in a significant disruption to critical services and could jeopardize participant safety and data integrity. Using the current contractor for the extension of services allows for continuity of operations in this highly regulated environment and helps to ensure we are able to maintain during this interim period the services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. This notice of intent is not a request for competitive proposals. However, responsible sources may express their interest by submitting a capability statement. All capability statements received within fifteen days from the date of the publication of this notice will be considered by the Government. A determination by the Government not to compete this proposed contract action based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. This proposed acquisition was previously published under a Research and Development Sources Sought Notice that was posted on the System for Award Management (SAM.gov) website on February 20, 2026 as notice number HHS–NIH–NIAID–RDSS–26–75N93026R00009. | 82% | Pre-Solicitation | 12/01/2026 |
This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award. | 81% | Awarded | Open |
This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award. | 81% | Awarded | Open |
Additional Details
Solicitation Number
RFP-NIAID-75N93024R00018
Archive Date
Feb 1, 2025
Place of Performance Country
AX1
Office Address
BETHESDA, MD, 20892